U.S. flag

An official website of the United States government

NM_004360.5(CDH1):c.602_603del (p.Pro201fs) AND Hereditary diffuse gastric adenocarcinoma

Germline classification:
Pathogenic (3 submissions)
Last evaluated:
Jan 10, 2025
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003064355.7

Allele description [Variation Report for NM_004360.5(CDH1):c.602_603del (p.Pro201fs)]

NM_004360.5(CDH1):c.602_603del (p.Pro201fs)

Gene:
CDH1:cadherin 1 [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
16q22.1
Genomic location:
Preferred name:
NM_004360.5(CDH1):c.602_603del (p.Pro201fs)
HGVS:
  • NC_000016.10:g.68808763_68808764del
  • NG_008021.1:g.76472_76473del
  • NM_001317184.2:c.602_603del
  • NM_001317185.2:c.-1014_-1013del
  • NM_001317186.2:c.-1218_-1217del
  • NM_004360.5:c.602_603delMANE SELECT
  • NP_001304113.1:p.Pro201fs
  • NP_004351.1:p.Pro201Argfs
  • NP_004351.1:p.Pro201fs
  • LRG_301t1:c.602_603del
  • LRG_301:g.76472_76473del
  • LRG_301p1:p.Pro201Argfs
  • NC_000016.9:g.68842666_68842667del
  • NM_004360.3:c.602_603delCT
Protein change:
P201fs
Molecular consequence:
  • NM_001317185.2:c.-1014_-1013del - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001317186.2:c.-1218_-1217del - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001317184.2:c.602_603del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_004360.5:c.602_603del - frameshift variant - [Sequence Ontology: SO:0001589]

Condition(s)

Name:
Hereditary diffuse gastric adenocarcinoma (HDGC)
Synonyms:
DIFFUSE GASTRIC AND LOBULAR BREAST CANCER SYNDROME
Identifiers:
MONDO: MONDO:0007648; MedGen: C1708349; Orphanet: 26106; OMIM: 137215

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003443629Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Dec 17, 2023)
germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

SCV004042966Myriad Genetics, Inc.
criteria provided, single submitter

(Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023))
Pathogenic
(Jun 9, 2023)
unknownclinical testing

Citation Link,

SCV005685087Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet
criteria provided, single submitter

(ACMG Guidelines, 2015)
Pathogenic
(Jan 10, 2025)
germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria.

Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N, Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B, MacLeod P, Micek M, Ford J, Foulkes W, Australie K, Greenberg C, LaPointe M, Gilpin C, Nikkel S, et al.

J Med Genet. 2004 Jul;41(7):508-17.

PubMed [citation]
PMID:
15235021
PMCID:
PMC1735838

Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice.

Guilford P, Humar B, Blair V.

Gastric Cancer. 2010 Mar;13(1):1-10. doi: 10.1007/s10120-009-0531-x. Epub 2010 Apr 7. Review.

PubMed [citation]
PMID:
20373070
See all PubMed Citations (5)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV003443629.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

This sequence change creates a premature translational stop signal (p.Pro201Argfs*7) in the CDH1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CDH1 are known to be pathogenic (PMID: 15235021, 20373070). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with hereditary diffuse gastric cancer (PMID: 24389957). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 2137843). For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Myriad Genetics, Inc., SCV004042966.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

From Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, SCV005685087.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

The following ACMG criteria was used: PVS1; PM2_SUP; PP1

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Feb 25, 2025